AQR Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

AQR Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$53.1K	Sell	22,675 -23,320	-51%	-$60.2K	﹤0.01%	3711
2025 Q4	$62.1K	Sell	45,995 -60,970	-57%	-$88.7K	﹤0.01%	3500
2025 Q3	$162K	Sell	106,965 -327,993	-75%	-$492K	﹤0.01%	3302
2025 Q2	$505K	Sell	434,958 -184,372	-30%	-$243K	﹤0.01%	2609
2025 Q1	$985K	Buy	619,330 +396,233	+178%	+$854K	﹤0.01%	2022
2024 Q4	$676K	Buy	223,097 +27,615	+14%	+$90.5K	﹤0.01%	2097
2024 Q3	$719K	Buy	+195,482	New	+$710K	﹤0.01%	2010
2022 Q2	–	Sell	-4,517	Closed	-$208K	–	2313
2022 Q1	$208K	Sell	4,517 -2,725	-38%	-$147K	﹤0.01%	2052
2021 Q4	$609K	Buy	+7,242	New	+$560K	﹤0.01%	1765

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

AQR Capital Management's ZNTL Position: Q1 2026 in Review

AQR Capital Management reduced its Zentalis Pharmaceuticals (ZNTL) stake by 51% in Q1 2026, selling an estimated $60.2K and leaving 22,675 shares worth $53.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3711.

AQR Capital Management first reported a position in ZNTL in Q4 2021 and has held it in 9 quarters since. The position peaked at $985K in Q1 2025. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

AQR Capital Management held 22,675 shares of Zentalis Pharmaceuticals worth $53.1K as of Q1 2026.
AQR Capital Management sold 23,320 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $60.2K.
Zentalis Pharmaceuticals made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #3711 holding.
AQR Capital Management first reported a position in Zentalis Pharmaceuticals in Q4 2021 and has held it in 9 quarters since.
AQR Capital Management's Zentalis Pharmaceuticals position peaked at $985K in Q1 2025.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.